Outlining Progress on NCATS’ AAV Gene Therapy Programs

Time: 1:30 pm
day: Clinical - PM

Details:

• Updates from the BGTC portfolio’s eight rare disease clinical trials, and version 1.0 of the BGTC standard operational playbook for clinical development of AAV gene therapies
• Highlighting the Platform Vector Gene Therapy (PaVe-GT) pilot project: it’s scope, goals, and latest updates
• Updates from Phase 2 of The NIH Somatic Cell Genome Editing consortium , including the TARGETTED genome editor delivery challenge

Speakers:

Philip John (P.J.) Brooks Philip J. (P.J.) Brooks is the Deputy Director of NCATS’ Division of Rare Diseases Research Innovation. He also is the working group co-coordinator for the Read more